Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA

Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs)...

Full description

Saved in:
Bibliographic Details
Published in:Cancer investigation 2018-02, Vol.36 (2), p.118-128
Main Authors: Psimadas, Dimitrios, Valotassiou, Varvara, Alexiou, Sotiria, Tsougos, Ioannis, Georgoulias, Panagiotis
Format: Article
Language:English
Subjects:
Antibodies
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - pharmacology
Antigens, Surface - immunology
Antigens, Surface - metabolism
Glutamate Carboxypeptidase II - immunology
Glutamate Carboxypeptidase II - metabolism
Humans
Isotope Labeling
Male
Molecular Imaging - methods
prostate cancer
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - therapy
PSMA
radiolabeling
Radiopharmaceuticals - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs) on the other hand are very important targeting biomolecules with high affinity that can "carry" the radioisotope of choice. Herein we make a brief overview of the radiolabeled mAbs that target prostate specific membrane antigen (PSMA) and their use in the management of patients with prostate cancer (PCa).
ISSN:0735-7907
1532-4192
DOI:10.1080/07357907.2018.1430816